Skip to main content

Table 4 Median time to 50 and 90% parasite reduction and recurrent infections up to day 28 (Study 1)

From: Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients

Group

1A

1B

1C

1D

N

34

30

30

19

Median time (h) to 50% parasite reduction (95% CI)

18.0 (12.0–24.0)

18.0 (6.0–24.0)

9.0 (6.0–18.0)

24.0 (12.0–24.0)

Median time (h) to 90% parasite reduction (95% CI)

30.0 (18.0–30.0)

24.0 (12.0–36.0)

30.0 (18.0–30.0)

24.0 (24.0–30.0)

Recurrences

14

13

15

8

PCR data available

12/14

11/13

10/15

8/8

New infection

9 (75%)

6 (54.5%)

6 (60%)

0

Recrudescences

3 (25%)

5 (45.5%)

4 (40%)

8 (100%)

  1. Recurrent infections were only analyzed in patients who were judged as successfully treated after 72 h
  2. Group 1A: 1 day IM to adults; Group 1B: 3 days IM to adults; Group 1C: 1 day IV to adults; Group 1D: 3 days IM to children